Number of Immuno-Oncology (IO) trials in China surge by more than 50% in 2016 and 2017, finds GlobalData

In recent years, China increased its focus on the clinical trial investigation of immuno-oncology (I/O) drug candidates. The number of clinical trials recorded a compound annual growth rate (CAGR) of ~34% since 2008, according to leading data and analytics company GlobalData.

GlobalData identified 819 clinical trials that have been initiated in the last 10 years (2008-17) to investigate I/O drug candidates. More than half (n=464) of these trials were initiated in 2016 and 2017.

Phase II clinical trials accounted for nearly 28% of the total clinical trials conducted in China, followed by Phase I (24%) and Phase I/II (24%).

In the I/O clinical trials, 67% of the trials were in progress, 24% were completed and 5% were planned. Out of these completed trials, 51% were reported with results.

FUDA Cancer Hospital is the major non-industry player investigating I/O drug candidates in China. The other top non-industry sponsors were China PLA General Hospital, Sun Yat-sen University.

Jiangsu Chia-tai Tianqing Pharmaceutical Co Ltd emerged as the top industry sponsor. Other top industry sponsors were Bristol-Myers Squibb Co., F. Hoffmann-La Roche Ltd and Novartis AG.

The major indications under investigation include Non-Small Cell Lung Cancer, Solid Tumor, Hepatocellular Carcinoma, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), and Breast Cancer, etc.


Analysts available for comment. Please contact the GlobalData Press Office at

More Media